Bruno Paiva

Experts Shaji Kumar, Elena Zamagni, and Bruno Paiva discuss novel technologies for risk stratification in smoldering myeloma. They explore AI-driven early intervention and advancements in treating smoldering myeloma, emphasizing patient-focused therapy decisions and effective screening strategies.

Experts discuss the challenges of sequencing BCMA therapies in multiple myeloma, the prognostic value of circulating tumor cells, and the growing role of quadruplet therapies. They explore optimal combinations and sequencing, the Perseus trial comparing DARA VRD and VRD treatments, and the use of Dara KRD for newly diagnosed myeloma patients.

Experts in multiple myeloma management discuss the use of MRD as primary endpoint for clinical trials, its potential as a treatment goal, and its applicability in clinical decision-making. The pros and cons of flow cytometry vs. next generation sequencing for MRD testing are explored, along with the importance of sensitivity and standardization. Available methods for managing multiple myeloma and the role of adherence in determining standardization are discussed. Efforts to standardize the use of flow in laboratories worldwide, improve reproducibility of data, and establish a quality control system are also highlighted.